SoFi stock falls after announcing $1.5B public offering of common stock
Director Robert F. Williamson III, purchased 9,498 shares of Perspective Therapeutics, Inc. (NASDAQ:CATX) common stock on November 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at a price of $2.10, totaling $19,945. Following the transaction, Williamson directly holds 108,982 shares and indirectly holds 9,864 shares through RFW3 Revocable Trust.
In other recent news, Perspective Therapeutics reported interim data from its ongoing Phase 1/2a clinical trial of its cancer treatment [212Pb]VMT-α-NET, showing an objective response rate of 44% in Cohort 2. Despite 14 of 16 patients remaining free from progression, the market reacted negatively, possibly due to expectations of stronger efficacy results. Oppenheimer responded by lowering its price target for Perspective Therapeutics to $13.00 from $14.00, while maintaining an Outperform rating, following the company’s third-quarter business update. Meanwhile, BTIG initiated coverage on Perspective Therapeutics with a Buy rating and a $14.00 price target, emphasizing the company’s leadership in next-generation radiopharmaceuticals. H.C. Wainwright reiterated its Buy rating and a $10.00 price target, following the treatment of the first patient in a new cohort of the company’s Phase 1/2a dose-finding trial. UBS also maintained its Buy rating and an $18.00 price target after the company’s second-quarter results highlighted progress in patient enrollment for its VMT-a-NET trial. These developments reflect the ongoing interest and varied expectations from analysts regarding Perspective Therapeutics’ potential in the radiopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.